This disclosure relates to the development of
nucleotide compositions directed to spliced
gene variants that generate circular RNAs that are indicative of Alzheimer's
disease. In some aspects, the nucleotides are siRNA compositions. In some aspects, the
circular RNA is from a backspliced variant produced from the MAPT
gene. The circular RNAs contain multiple
microtubule binding domains and feature no frame shift and no
stop codon when translated, allowing for consistent production. The siRNA compositions disclosed herein demonstrate good
efficacy at silencing expression of the circRNAs. Circular RNAs, including tau circular RNAs exhibit a dramatic increase in translation after undergoing A>I editing, i.e.
deamination of adenosines to inosines, which causes the formation and accumulation of
pathological proteins. This accumulation can be prevented by siRNAs. In addition, five circular RNAs have been identified that correlate in expression levels with Alzheimer's
disease severity. These circRNAs express proteins after
adenosine to
inosine editing. Part of these circproteins are specific for circular RNAs and could be molecular markers for Alzheimer's
disease, accessible from
cerebrospinal fluid.